Next Event in Series
Harnessing Cross-Fibrosis Insights for Better Development Decisions
December 1-3, 2026 | Boston, MA
Building Predictive Preclinical Packages, Deciphering Necessary Changes to Clinical Protocols & Exploring Novel Mechanisms to Move Beyond Slowing FVC Decline to Improving Patients' Quality of Life
Uniting the Full Spectrum of Stakeholders to Capitalize on the Industry’s Momentum
For a decade, the IPF Summit has been the go-to intimate discussion-based forum uniting stakeholders across the pulmonary fibrosis landscape, and this year, the conversation had never been more critical.
As a wave of positive Phase III readouts from Boehringer Ingelheim and United Therapeutics reshapes the treatment landscape, IPF has entered a new era, even more complex than before.
With multiple therapies emerging, evolving standards of care, and increasing pressure to demonstrate differentiated value, the question is no longer if we can develop effective treatments, but how to do so smarter, faster, and with greater impact for patients.
The 10th IPF Summit was the only end-to-end, industry-led meeting designed to tackle this head-on.
Bringing together over 150 experts across discovery, translational science, and clinical development, from leading companies including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, Contineum Therapeutics, Mediar Therapeutics, and many more.
Offering a uniquely integrated view of challenges and opportunities defining the next decade of IPF drug development, from novel biology and biomarker-driven strategies to next-generation trial design and combination approaches, this is where leaders came together to align on what success looked like.
For those looking to stay competitive in a rapidly evolving field, this was the room they needed to be in.
A small event where many people were able to share in an open conversation rather than just listen to presentations. “The diversity of topics across innovative biology and clinical development in a small setting makes this a unique conference.
Altos Labs
Complete scope of work from concepts to clinical development and possibly approval. Excellent personal interactions with academics and biotechnology company representatives.
JN Nova Pharma Inc.
I truly appreciate the scale of the summit and the diversity of attendees, ranging from small biotech and large pharma to clinicians and academics. This diversity creates a valuable opportunity for cross-disciplinary learning, identification of gaps, and alignment on the trajectory of IPS/ILD research. Additionally, it fosters collaborations among experts from various fields.
Takeda
Explore the 2026 Full Event Guide
- Learn from 40+ Expert Speakers
- Brand-New ILD & PPF Focus Day dedicated to ILDs & PPF & the nuances of drug development
- Brand-New Investor Panel with insights into building conviction early on to generate real investor confidence & more
- Structured Dual-Tracked Content Days Covering Emerging Biology & Early Translation, as well as Late Translation & Clinical, to tackle the most pressing challenges at that stage of development
2026 Expert Speaker Faculty Included
2026 Partners
Attending Companies Included
Explore our Agenda
Hear the latest industry updates and gain exclusive insights during our packed discussion-led agenda.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is directly in front of IPF, ILD & PPF decision makers.
Join Quality Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during dedicated networking sessions.